Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says
Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on average 50.3 lb (22.8 kg) while those treated with semaglutide lost 33.1 lb (15 kg), translating to a 47% greater relative weight loss with tirzepatide.
Ozempic maker Novo Nordisk says it has developed a compound that’s shown to be a one-two punch for appetite suppression and ...
While President-elect Donald Trump looks poised to scrap many policies of the Biden administration, one veteran analyst says ...
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...
Researchers have developed and are testing a small, implanted gastric balloon that people can inflate or deflate to feel full ...
A registered dietitian shares the best diet and exercise tips to help optimize your GLP-1 response for faster weight loss.
If you're in a relationship that faces struggles with weight and are considering GLP-1 medications like Ozempic, consider ...
Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback